Results 11 to 20 of about 64,054 (239)

Neurological immune-related adverse events after ICI treatment: a protocol for an overview of systematic reviews [PDF]

open access: yesBMJ Open
Introduction Immune checkpoint inhibitors (ICIs) have become an important treatment option for selected cancer patients in recent years. In this overview of systematic reviews, we aim to present a comprehensive summary of the evidence on neurological ...
Christian Gunge Riberholt   +6 more
doaj   +4 more sources

Dataset for: Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune-related adverse events [PDF]

open access: yesData in Brief
The rise of cancer immunotherapy has been a milestone in clinical oncology. Above all, immune checkpoint inhibitor treatment (ICI) with monoclonal antibodies targeting programmed cell death protein 1 (PD-1), programmed cell death-ligand 1 (PD-L1), and ...
Leonie Müller-Jensen   +13 more
doaj   +4 more sources

Neurological Immune-Related Adverse Events in Patients Treated with Anti-Programmed Death 1 Agent, Pembrolizumab: A Case Series [PDF]

open access: yesCase Reports in Neurology
Background: This case series highlights the various clinical manifestations of pembrolizumab-induced neurological adverse events, offering insights into the spectrum of immune-related neurological adverse events associated with immune ...
Sepehr Khosravi   +3 more
doaj   +4 more sources

Case Report: Neurological immune-related adverse events with anti-PD-1 based immunotherapy in cervical cancer [PDF]

open access: yesFrontiers in Oncology
Despite recent advances in screening and primary prevention, cervical cancer (CC) still represents the fourth leading cancer in terms of incidence and mortality among women.
Gaia Passarella   +8 more
doaj   +4 more sources

Predictors for the development of neurological immune‐related adverse events of immune checkpoint inhibitors and impact on mortality [PDF]

open access: yesEuropean Journal of Neurology, 2023
AbstractBackground and purposeLittle is known about risk factors for developing neurological immunological adverse events (neuro‐irAEs) from immune checkpoint inhibitors (ICIs). We report the incidence, predictors for development, impact on mortality of neuro‐irAEs, and impact of ICIs on pre‐existing neurological conditions in a large clinical cohort ...
Chen Yan   +8 more
openaire   +4 more sources

The Immune System’s Echo: The Phenomenon of Delayed Neurological Immune-Related Adverse Events (NirAEs) in Adjuvant Immunotherapy [PDF]

open access: yesCureus, 2023
The use of immune checkpoint inhibitors (ICIs) in early-stage settings has shown promise but can lead to chronic immune-related toxicities known as delayed immune-related adverse events (DIREs). These events, occurring after immunotherapy cessation, can affect various organ systems.
Gohel, Shruti   +3 more
openaire   +4 more sources

Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologist [PDF]

open access: yesJournal of Neurology, Neurosurgery & Psychiatry
Immune checkpoint inhibitors (ICI) have had a dramatic effect on cancer outcomes with their use increasing as indications expand. Despite impressive efficacy across a range of tumour types, their role in activating the immune system results in frequent immune-related adverse events (irAE).
Mark D Willis   +4 more
openaire   +3 more sources

Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases [PDF]

open access: yesJournal for ImmunoTherapy of Cancer, 2018
Background PD-1 and CTLA-4 inhibitors are associated with several adverse events including a spectrum of immune-related adverse effects (irAEs). Neurologic irAEs are uncommon occurrences with varied presentations.
Christine A. Garcia   +6 more
doaj   +3 more sources

Unravelling the Acute, Chronic and Steroid-Refractory Management of High-Grade Neurological Immune-Related Adverse Events: A Call to Action [PDF]

open access: yesBrain Sciences
Rare side effects of immune-checkpoint inhibitors (ICIs) are known as neurological immune-related adverse events (n-irAEs). Typically, n-irAEs affect the peripheral nervous system, primarily presenting as myositis, polyradiculoneuropathy, or cranial neuropathy. Less commonly, they impact the central nervous system, resulting in encephalitis, meningitis,
Antonio Malvaso   +7 more
openaire   +5 more sources

Neurologic immune-related adverse events from immune checkpoint inhibitors: recent advances and future prospectives

open access: yesImmunological Medicine
Immune checkpoint inhibitors (ICI) have transformed cancer therapy but can disrupt immune tolerance, causing immune-related adverse events (irAE) in various organs.
Tomoya Kawazoe   +2 more
doaj   +3 more sources

Home - About - Disclaimer - Privacy